CD23 expression in non‐Hodgkin lymphoma: Immunohistochemical demonstration using the antibody BU38 on paraffin sections
- 1 October 1991
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 165 (2) , 125-128
- https://doi.org/10.1002/path.1711650207
Abstract
The leucocyte antigen CD23 is upregulated in the early stages of B‐cell activation by Interleukin‐4 (IL‐4), and functions as an IgE receptor and lymphocyte growth factor. We have studied the expression of CD23 in 68 cases of non‐Hodgkin lymphoma (NHL) using the antibody BU38. This new antibody has the great advantage of being applicable to routinely‐processed paraffin sections. CD23 was expressed in tumour cells in 27 out of 36 cases of low grade NHL and 3 out of 32 cases of high grade NHL. Follicular dendritic cells were strongly positive and were seen in follicular lymphomas. Macrophages were also positive and were numerous in high grade lesions.Keywords
This publication has 9 references indexed in Scilit:
- Immunohistochemical determination of CD23 expression in Hodgkin's disease using paraffin sectionThe Journal of Pathology, 1990
- CD23: a multi-functional receptor/ lymphokine?Immunology Today, 1989
- B–cell memory is short-lived in the absence of antigenNature, 1988
- Activation and differentiation antigen expression in B-cell non-Hodgkin's lymphomaThe Journal of Pathology, 1988
- Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti‐Bp50 (CDw40)European Journal of Immunology, 1988
- Expression of Fcϵ receptors on activated human T lymphocytesEuropean Journal of Immunology, 1987
- Fc epsilon receptor, a specific differentiation marker transiently expressed on mature B cells before isotype switching.The Journal of Experimental Medicine, 1986
- Ligation of the CD23, p45 (BLAST‐2, EBVCS) antigen triggers the cell‐cycle progression of activated B lymphocytesEuropean Journal of Immunology, 1986
- Steady-state magma discharge at Etna 1971–81Nature, 1981